ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using ...

ACTON, Mass., June 06, 2026--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced new clinical results ...

First participant enrolled in randomized control trial designed to demonstrate safety and efficacy of Insulet’s fully closed-loop automated insulin delivery system versus standard therapy Unique ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared the first tubeless hybrid closed-loop insulin delivery system for people with type 1 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. NEW ORLEANS — New data show sustained glycemic ...

A closed-loop system—commonly referred to as an artificial pancreas—could one day manage a user’s diabetes around the clock, eliminating the need for fingersticks, regular check-ins with a glucose ...

The possible advantage of hybrid closed-loop therapy (i.e., artificial pancreas) over sensor-augmented pump therapy in very young children with type 1 diabetes is unclear. In this multicenter, ...

Closed-loop control systems of insulin delivery may improve glycemic outcomes in young children with type 1 diabetes. The efficacy and safety of initiating a closed-loop system virtually are unclear.